Immuneering jumps after positive initial data on cancer therapy

Immuneering

13/09/2024 15:16

** Shares of cancer drug developer Immuneering Corp  IMRX.O 
jump ~72% to $2.50
    ** Co says its pancreatic cancer therapy, IMM-1-104, reduced
or eliminated tumors in 40% of the five patients tested in a
mid-stage study 
    ** Co expects to report data from at least another group of
patients in the mid-stage study by year-end 
    ** Despite session gains, stock still down ~67% YTD

 (Reporting by Kashish Tandon)
 ((Kashish.tandon@thomsonreuters.com))